Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

(2019) Ana Fernández Montes et al.   Cancer Medicine

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study

(2018) Alessandro Pastorino et al.   Clinical Colorectal Cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

(2018) Jaafar Bennouna et al.   JAMA Oncology

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA

(2017) Jasmina I. Ivanova et al.   MEDICAL ONCOLOGY

Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database

(2017) Amandine Gouverneur et al.   Targeted Oncology

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

(2016) J. Feliu et al.   Clinical & Translational Oncology

Why do we need observational studies of everyday patients in the real-life setting?: Table 1

(2015) Alexander T. Cohen et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

Metastatic Colorectal Cancer: Current State and Future Directions

(2015) Marwan G. Fakih   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

(2015) Tessa Kennedy-Martin et al.   Trials

Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence

(2014) C M Booth et al.   BRITISH JOURNAL OF CANCER

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

(2013) Josep Tabernero et al.   EUROPEAN JOURNAL OF CANCER

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY